845 results about "Tumor cell apoptosis" patented technology

A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles or microparticles (e.g., cross-linked gelatin) of the therapeutic agent (e.g., paclitaxel) also may be used. The nanoparticles or microparticles may be coated with a bioadhesive coating. Microspheres that agglomerate to block the entrance of the lymphatic ducts of the bladder to retard clearance of the microparticles through the lymphatic system also may be employed. This invention also uses drug-loaded gelatin and poly(lactide-co-glycolide) (PLGA) nanoparticles and microparticles to target drug delivery to tumors in the peritoneal cavity, bladder tissues, and kidneys.

The invention provides an FPGA (field programmable gate array) control-based all-solid-state high-voltage nanosecond pulse generator, and belongs to the field of bio-electromagnetic technology. The nanosecond pulse generator mainly comprises a power supply system, a pulse forming system, a pulse measurement system, an FPGA control system, a signal conversion system and a portable computer. In the generator, the output pulse amplitude is between 0 and 10kV, the pulse width is between 200 and 1000ns, the pulse frequency is between 1 and 1000Hz, the falling edge is between 30 and 40ns, the number of pulse is between 1 and 1000, and particular parameters are determined according the requirement of tumor treatment. The FPGA control-based all-solid-state high-voltage nanosecond pulse generator has the characteristics of intelligent regulation of pulse parameters (pulse amplitude, width, frequency and number), optical fiber transmission, high parameter accuracy, long service life, small size, low failure rate, good security and the like; and the generator outputs high pulse frequency, and is advantageous to quick searching of the optimal window parameters for inducing tumor cell apoptosis by virtue of intelligent regulation, so that the tumor treatment effect is improved. The FPGA control-based all-solid-state high-voltage nanosecond pulse generator can be widely applied to tumor treatment.

The invention discloses application of dihydromyricetin in preparing a medicine for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor. In particular, the application is to prepare medicines for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor, preventing and treating arrest of bone marrow and baldness, resisting mutation, preventing and treating the generation of secondary tumors, preventing and treating tumor transfer, and preventing and treating breast cancer, cervical carcinoma, intestinal cancer and the like. The invention creatively finds that the dihydromyricetin has the effects of removing free radicals, inhibiting reaction chains of the free radicals, resisting the mutation, inhibiting the expression of the tumor gene, causing the death of tumor cells, preventing and treating the tumor generation, preventing and treating the secondary tumors and the transfer of the secondary tumors and preventing and treating infection. Therefore, as the medicine for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor, the dihydromyricetin can inhibit and alleviate chemical damage, prevent and treat damage of a mutagen and further prevent gene mutation or the secondary tumors; and by combination with the radiotherapy and chemotherapy, the effects of preventing untoward reactions in radiotherapy and chemotherapy of tumor and preventing generation of tumors are achieved.

The invention discloses a PD-L1 affinity peptide P1 with anti-tumour activity, which is the polypeptide obtained by phage display peptide library screening, wherein the amino acid sequence thereof is FPNWSLRPMNQM, and the molecular weight thereof is1520.7. The affinity peptide P1 with anti-tumour activity and aiming at a PD-L1 target disclosed by the invention has the advantage of being screened with a high flux by utilizing a phage display peptide library screening technology for the first time; and via an in-vivo tumour-bearing experiment for Kunming mice, the affinity peptide P1 disclosed by the invention is proved to have a great anti-tumour activity, can induce the internal tumour cell apoptosis of mice, and have an extremely high killing capacity for tumour cells. Via the affinity peptide P1 disclosed by the invention, new thoughts and theoretical basis are provided for research and development on medicines based on PD-L1.

The invention belongs to the technical field of the molecular biology and the biomedicine, and particularly relates to application of a gRNA sequence based on a CRISPR / Cas9 system to cause tumor cell apoptosis. According to the design principle of CRISPR / Cas9, two target points are designed on a human genome, and corresponding oligos is synthesized and established on a px458 carrier. The CRISPR / Cas9 system guided by the gRNA is established in a human hepatoma cell line (HepG2) according to the design of the two target points, a human TCAB1 gene can be effectively knocked out, the system is easy to operate, and the knockout efficiency of the human TCAB1 gene is high. The CRISPR / Cas9 system guided by the gRNA can be expected to be applied in novel tumor treating medicine.

A device for inducing apoptosis of tumor cell with high voltage nanosecond pulse belongs to technology field of electric impulse for treatment of tumor. The inventive device mainly comprises high voltage direct current module, pulse formation system, pulse measurement system, computer system, and power system. Amplitude value of high voltage nanosecond pulse is continuously regulated or preset between 0-9.9kV, repetition frequency is continuously regulated or preset between 2-100Hz, width is continuously regulated or preset between 200ns-1 mu s by separating to 7 grades, and numbers is regulated or preset according to treatment requirement. As the inventive device can induce apoptosis of tumor cell, is an unalloyed physical method, has no requirement of medicament assistance, thus can completely avoid toxic and adverse side effect of chemotherapeutics during treatment and adverse reaction such as inflammation, pain, ulcer and stammer, therefore the inventive device can be widely used in oncotherapy and treatment of removing polypus and redundant grease and vulvopathy.

Compositions and methods for restoring killing of cancer cells are provided. Preferably, the compositions are administered to a subject in an effective amount to antagonize, inhibit, reduce, or block B7-H1 mediated signal transduction in cancer cells expressing B7-H1. It has been discovered that B7-H1 transmits an anti-apoptotic signal in cancer cells that increases the resistance of the cancer cells to CTL mediated cytolysis and to Fas induced cell death. It is believed that blocking the transmission of the anti-apoptotic signal by B7-H1 increases the susceptibility of the cancer cells to apoptosis and CTL cytolysis thereby enhancing the death of cancer cells. Preferred compounds or B7-H1 antagonists include antibodies that bind to B7-H1, B7-H1 receptors, or ligands of B7-H1 such as PD-I or B7-1. Additional B7-H1 antagonists include small molecules, for example small molecules that bind the cytoplasmic portion of B7-H1 or the extracellular portion of B7-H1 and inhibit, reduce, block or interfere with B7-H1 signal transduction. Methods for treating one or more symptoms associated with cancer or hyperproliferation are also provided.

The invention discloses a total bufogenin extract with antitumor function and also discloses a preparation method of the extract and application thereof in the preparation of antitumor medicines. The total bufogenin extract of the invention is prepared by organic solvent extraction, column chromatography separation and purification of dried toadskin; the content of total bufogenin is over 80 percent, wherein the content of resibufogenin is over 12 percent, the content of cinobufagin is over 4 percent, and the content of bufotalin is over 10 percent. Compared with the prior art, the invention eliminates bufotenine alkaloid which has irritation, is easy to cause hypersensitivity but has no antitumor activity, efficiently collects the effective part of total bufogenin which has significant antitumor activity, therefore pharmacological action is stronger, the clinical curative effect is higher and the toxic and side effect is lower. The total bufogenin extract can be prepared into various pharmaceutical preparations for clinical application, therefore the invention has the functions of killing tumor cells, inducing differentiation and apoptosis of tumor cells, inhibiting the neovascularization of tumor cells and lowering the neoplasm metastasis rate, etc.

The invention relates to a portable high-voltage nanosecond squarer which belongs to a medicinal device for inducing cancer cell apoptosis by using a high-voltage nanosecond square wave pulse electric field. The portable high-voltage nanosecond squarer mainly comprises a power supply system, a high-voltage direct current module, a low-voltage power supply, a pulse forming system and a pulse shaping and counting system. The portable high-voltage nanosecond squarer has output pulses with highest amplitude of 15kV, pulse width adjustment range of 50ns-1us, rising edge gradient of reaching 10ns and controllable recurrence frequency of 0.2-15Hz; and the quantity of the output pulses of the portable high-voltage nanosecond squarer can be set. The portable high-voltage nanosecond squarer can be adjusted in multiple-parameters (pulse amplitude, pulse width, recurrence frequency, pulse quantity and the like), large-range and flexible and independent way, and is beneficial to researching the optimal window parameter of the cancer cell apoptosis and promoting the cancer cell apoptosis as well as improving the cancer treatment effect. Meanwhile, the portable high-voltage nanosecond squarer has compact and light structure, reliable work, simple operation and convenient popularization and application, and can be widely applied to the treatment of various cancers.

The present invention provides compositions and methods for generating and cryopreserving dendritic cells with superior functionality in producing stronger signals to T cells, resulting in a more potent DC-based anti-tumor vaccine. The present invention includes mature, antigen loaded DCs activated by Toll-like receptor agonists that induce clinically effective immune responses, preferably when used earlier in the disease process. The DCs of the present invention produce desirable levels of cytokines and chemokines, and further have the capacity to induce apoptosis of tumor cells. The cells can be cryopreserved and thawed for later use, thereby reducing the need for repeated pheresis and elutriation processes during vaccine production. These methods can also be utilized to directly target molecules involved in carcinogenetic signaling pathways and cancer stem cells.

The invention provides, in a general sense, a new labeling strategy employing compounds that are are N2S2 chelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a disease receptor targeting ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD31, monoclonal antibody CD40, capecitabine, a COX-2 inhibitor, deoxycytidine, fullerene, herceptin, human serum albumin, lactose, leuteinizing hormone, pyridoxal, quinazoline, thalidomide, transferrin, or trimethyl lysine. The present invention also pertains to kits employing the compounds of interest, and methods of assessing the pharmacology of an agent of interest using the present compounds.

The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.

The invention relates to an anticancer composition and application thereof. The anticancer composition comprises dithioamides or / and oxyquinolines with metallic element combining capacity, organic or / and inorganic salts containing copper or / and zinc, Chinese herbal medicine extract and pharmaceutically acceptable carrier or solvent, wherein the Chinese herbal medicine comprises at least one of ginseng, radix astragali, wolfberry fruit, mulberry, Rabdosia rubescens, gromwell, radix salviae miltiorrhizae, pseudo-ginseng, peach kernel, eucommia and oldenlandia. The Chinese herbal medicine in the anticancer composition can obviously enhance the inhibiting action of the dithioamides or / and oxyquinolines + copper or / and + zinc on human tumor cells, improve the treatment effect of inducing apoptosis of tumor cells, reduce the toxic and side effect and obviously inhibit tumor growth, thereby enhancing the life quality of the patients with tumors and prolonging the survival time of the patients with tumors.

The invention discloses a new use of phenanthridine biologic alcali of general formula I containing coumarone and its derivant in preparing anti-hepatitis b virus medicament.The biologic alcali has tumor cell apoptosis inducing effect, has strong inhibiting activity against to such pathogen, has antiviral effect, and is expected for treating liver cancer, wherein R1 to R10, R12 and R13 is hydrogen, hydroxy, carbon chain or naphthenic base with 1-12 carbon atoms, alkoxyl or acyloxy group, benzyloxy, chlorine and other halogen atoms, amino group, methylol, aldehyde group, carbonyl, acetonyl, carboxy, sulacyloxy, 4-methyl-benzenesulfonyloxyl, arylsulfonyloxy, diphenylphosphonoxyl and -OCONH2; R11 is hydrogen, methyl or oxygen atom; R14 and R15 are respectively hydrogen or methyl.

The invention provides a tumor vaccine and a preparation method thereof. The tumor vaccine comprises cell vesicles from apoptosis tumor cells and an adjuvant. The invention also provides a preparation method of the tumor vaccine. The method comprises the steps of: irradiating tumor cells by ultraviolet ray to realize tumor cell apoptosis, collecting cell vesicles released by the tumor cells; and mixing the cell vesicles with the adjuvant to form the tumor vaccine. The tumor vaccine provided by the invention comprises wide and comprehensive tumor antigen spectrums, overcomes the defect of incapability to killing wide tumor cells in the prior art, and has good usage security and immunization targeting.

The invention discloses an integration microfluidic chip used for cell apoptosis research and the application thereof. The chip mainly comprises a concentration gradient generating unit and an array cell culture unit, and each outlet opening of the concentration gradient generating unit positioned in the upstream of the chip is connected with a row of cell culture chambers positioned in the down stream of the chip through a dam-shaped structure. The invention creatively integrates the concentration gradient generation, the culture, the stimulation, the washing, the marking of chip cells and the detection of multi cell responses on the chip, and is applicable to the research of clinical drug-induced tomour cell apoptosis. Compared with the traditional porous plate technology, the invention saves the complex operations for preparing drug solutions with different concentration, greatly simplifies the cell seeding, stimulated, washing and marking operation processes, obviously reduces the consumption of the cells and reagent, and can get a plurality of experiment parameters through operating the invention once.

The invention relates to a design technology for fusion protein and a protein expression and purification technology, and relates the application of fusion protein as a tumor therapeutic medicament. The invention is characterized by fusing the 114th-281th amino acid of tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) with human IgGlFc. The fused protein consists of 400 amino acids, the isoelectric point pI is 9.34, and theoretical molecular weight is 45535.30. The protein exists by a dimer or a trimer, can remarkably induce apoptosis of a plurality of kinds of tumor cellsand kills or / and inhibit tumor cells in an animal body. Compared with TRAIL, the TRAIL-Fc fusion protein has large molecular weight, high activity and long vivo half-life, is expressed by mammalian cells, and can be used as a tumor therapeutic medicament.

The invention discloses a nitric oxide (NO) donor-type farnesyl thiosalicylic acid (FTA) derivative, and pharmaceutically acceptable salt, a preparation method and medical application thereof. The FTA derivative is a compound obtained by carrying out heterozygosis on a NO donor furazan nitrogen oxide and Ras protein inhibitor FTA by an ester bond or an amido bond. Pharmacological test results show that the FTA derivative can reserve the Ras protein inhibiting activity of FTA and simultaneously releases high-concertration NO to induce cancer cell apoptosis and enhance the inhibiting action on cancer cell proliferation; compared with the FTA, the FTA derivative has more excellent anti-tumor activity, and therefore, the compound can be suitable for treating various clinical malignant tumours.

The invention discloses an application of miltirone in preparation of antitumor drugs. The miltirone has a structure of formula I; the miltirone serves as an inhibitor of STAT3 (Signal Transducer and Activator of Transcription 3) and is capable of inhibiting growth and proliferation of tumor cells which are abnormally activated by STAT3 so as to cause the apoptosis of the tumor cells and also capable of improving sensibility of cytotoxic drugs and inhibiting formation of tumor vessels. The miltirone with the structure of formula I can inhibit STAT3 kinase Tyr705 phosphorylation level to achieve the functions of accelerating the apoptosis of the tumor cells, improving the sensibility of chemotherapy drugs and inhibiting formation of new vessels; and the proliferation of tumor cells can be significantly inhibited due to the combined combination of the miltirone with low toxicity or non-toxic concentration and adriacin doxorubicin with low toxicity or non-toxic concentration and the combined application of the miltirone and cis-platinum with low toxicity or non-toxic concentration. The functions of the miltirone with the structure of formula I have positive significance to prevention and treatment of tumors.

The invention discloses two halogenated 8-hydroxyquinoline platinum (II) complexes and a synthesis method and application thereof. The structures of the halogenated 8-hydroxyquinoline platinum (II) complexes are shown in the formula (I), and the synthesis method comprises the steps that an 8-hydroxyquinoline derivative and dichloro bis(dimethyl sulfoxide) platinum are taken and subjected to a coordination reaction in a polar solvent, and the halogenated 8-hydroxyquinoline platinum (II) complexes are obtained. It is shown through experiments carried out by an applicant that the halogenated 8-hydroxyquinoline platinum (II) complexes have good activity of inhibiting the proliferation of certain tumor cell strains and can selectively inhibit the growth of bladder cancer T-24 cells, and the apoptosis of the tumor cells is induced under the function of targetedly interfering with mitochondria; meanwhile, the toxicity of the complexes to human normal cells HL-7702 is low. The structures of the halogenated 8-hydroxyquinoline platinum (II) complexes and the structure of the 8-hydroxyquinoline derivative are shown in the following formulas (I) and (II) respectively, wherein the formulas (I)and (II) are shown in the description, and R1 represents Cl or Br.

The invention discloses a sodium nitroprusside-conjugated medicine-carrying prussian blue analogue nano-photothermal therapeutic agent and a preparation method thereof. The particle size of the sodiumnitroprusside-conjugated medicine-carrying prussian blue analogue nano-photothermal therapeutic agent prepared by a hydrothermal reaction method is 205.4nm, and passive targeting can be achieved by means of an enhanced permeability and retention (EPR) effect of a tumor site. Under the illumination of near-infrared laser, the nano-photothermal therapeutic agent can not only induce photothermal ablation of tumor cells through excellent photothermal conversion efficiency, but also can control NO release, thereby improving the EPR effect and increasing intratumoral delivery of nanoparticles. Furthermore, the NO can also inhibit tumor progression by inducing apoptosis of the tumor cells, preventing angiogenesis, reversing multidrug resistance, and the like. On the other hand, due to the structural difference between sodium nitroprusside and potassium ferricyanide, the lattice defects of the nanoparticles are caused, and the drug loading capacity of the nano-photothermal therapeutic agent is accordingly increased. Therefore, after chemotherapeutic drugs are carried, under the irradiation of near-infrared light, the nano-photothermal therapeutic agent can realize dose-controlled NO release and phototherapy and chemotherapy combined oncotherapy. In addition, the sodium nitroprusside-conjugated medicine-carrying prussian blue analogue nano-photothermal therapeutic agent provided by theinvention also has good photothermal stability and certain photoacoustic contrast properties.

The invention belongs to the technical field of tea production, and particularly relates to a Tetrastigma hemsleyanum Duels et Gilg tea with high contents of Tetrastigma hemsleyanum Duels et Gilg flavone, polysaccharide and kaempferol, and a manufacturing method of the Tetrastigma hemsleyanum Duels et Gilg tea. The method comprises the following steps: (1), spreading fresh Tetrastigma hemsleyanumDuels et Gilg leaves for 10-20 minutes; (2), fixation: deactivating enzymes of the Tetrastigma hemsleyanum Duels et Gilg leaves by adopting a microwave tea fixation drier; (3), flat pressing for shaping: uniformly spreading the Tetrastigma hemsleyanum Duels et Gilg leaves subjected to fixation on a bamboo skin board, and pressing another bamboo skin board on the leaves to enable the cooled Tetrastigma hemsleyanum Duels et Gilg leaves to be shaped; and (4), drying: drying the semi-finished products processed in the step (2) by a microwave tea machine. The Tetrastigma hemsleyanum Duels et Gilg tea is natural green, is bright green in color and light green in grounds, does not contain caffeine, is rich in Tetrastigma hemsleyanum Duels et Gilg flavone, polysaccharide, kaempferol and other ingratiates, can effectively inhibit cancer cell proliferation, promotes cancer cell poptosis, has no toxic or side effects and is easy to absorb and beneficial to health. The Tetrastigma hemsleyanum Duels et Gilg leaves are tender, have less fibers, and can be eaten after being brewed.

The invention relates to an ultrahigh-pressure extraction process of tricholoma matsutake polysaccharide. In the process, tricholoma matsutake is used as a raw material, and the active ingredient polysaccharide of tricholoma matsutake is extracted through the ultrahigh-pressure extraction process, so that a high-concentration raw material is provided to the medical application and healthcare of tricholoma matsutake; the tricholoma matsutake polysaccharide extracted by the process has obvious anti-tumor effects on enhancing immunity of an organism, inhibiting tumor cell proliferation, inducing tumor cell apoptosis and the like; moreover, the tricholoma matsutake polysaccharide also has a function of improving immunity, can be applied to the healthcare products and medicines for resisting tumor and improving immunity, and can be used as a food freshening agent or an additive of food, brewed wine, tobacco and cosmetics.

The invention provides a TNF (Tumor Necrosis Factor)-related apoptosis-inducing ligand fusion protein of extracellular parts and an XVIII type collagen NC1 domain or a trimerization domain, wherein the peptide adapter is [GlyGlyGlyGlySer]n, wherein the n is an integer of 0-4. The fusion protein is constructed and recombined; and the fusion protein is expressed for annealing, wherein the fusion protein after the annealing is expressed into relatively strong induced tumor cell apoptosis activity. According to the invention, the design of the fusion protein VXIII type collagen NC1 domain fusion TRAIL (Tnf Related Apoptosis Inducing Ligand) is adopted so that the half-life period of the related fusion protein in an experimental animal body can be prolonged and the defect that the half-life period of the TRAIL is just a little number of minutes can be overcome; the NC1 or trimerization domain has very strong trimerization characteristics and can stabilize a trimer thereof after the TRAIL is infused so as to keep to induce the tumor cell apoptosis activity; the endostatin domain contained in the NC1 domain has the effect of inhibiting the production of new vessels, and the effect can be cooperated with the apoptosis effect of the TRAIL so as to strengthen the anti-tumor effect of the infusion protein. The method disclosed by the invention can efficiently reduce the cost of the infusion protein production in a laboratory or in industry.

This invention provides a method for increasing apoptosis in tumor cells and a method of decreasing a size of a tumor, said methods comprising contacting the tumor cells with: a) an effective amount of at least one antitumor chemotherapeutic agent and b) an effective amount of a ceramide, sequentially or concomitantly, wherein the apoptosis induced by the combination of the antitumor chemotherapeutic agent and the ceramide is greater than the apoptosis induced by contact of the tumor cells with either the antitumor chemotherapeutic agent alone or the ceramide alone. This invention also provides a method of treating cancer in a subject which comprises a method according to either of the above-described methods. This invention provides a method for treating cancer in a subject comprising administering to the subject an effective amount of at least one antitumor chemotherapeutic agent and an effective amount of at least one ceramide, sequentially or concomitantly. This invention provides a pharmaceutical composition comprising at least one antitumor chemotherapeutic agent in an amount effective to induce apoptosis of tumor cells and at least one ceramide in an amount effective to induce apoptosis of tumor cells and a pharmaceutically acceptable carrier.

The present invention relates to a kind of amino group or halogen substituted 8-oxy-8H-acenaphthenee[1, 2-b] pyrrolyl-9-nitrile derivatives and their biological use. They are applied mainly in intracorporeal and extracorporeal inducing cell apoptosis and as anticancer compound. These compounds are 3, 6-disubstituted, 3-disubstituted or 6-substituted 8-oxy-8H-acenaphthenee[1, 2-b] pyrrolyl-9-nitrile derivatives. They can induce tumor cell apoptosis and block cell period in the dosage dependent mode within the wide concentration range of 0.01-10 micro mole. The highest activity compound B1 has IC50=0.17 micro mole (0.56 micro gram). When they are used in animal tumor model body, they can inhibit tumor growth obviously in inducing cell apoptosis mode. Therefore, the present invention is one kind of apoptosis inducing agent and antitumor compound with high activity.

The invention belongs to the technical field of genetic engineering drugs, and discloses a double-target-spot fusion protein capable of enhancing the TRAIL antitumor activity. The cDNA sequence of the overall-length fusion gene sequence 1 is shown in SEQ ID NO1; the coding amino acid sequence of the overall-length fusion gene sequence 1 is shown in SEQ ID NO2; the coding cDNA sequence of the overall-length fusion gene sequence 2 is shown in SEQ ID NO4; and the coding amino acid sequence of the overall-length fusion gene sequence 2 is shown in SEQ ID NO5. In comparison with the prokaryotic expression carrier of separate TRAIL protein soluble fragment coding cDNA sequence, the fusion protein of the prokaryotic expression carrier has higher soluble expression, and the recycling and purifying efficiency of the fusion protein is higher; and the in-vitro biological activity analysis indicates that the fusion protein can activate death receptors on the cell membrane and inhibit expression of an XIAP gene in the cell plasma, enhance the activity of inducing tumor cell apoptosis through the double-target-spot function in apoptotic pathway and ensure stronger antitumor effect.

The invention provides a preparation method of a chalcone derivative, relates to an preparation method of a chalcone, and aims at finding the chalcone derivative with the action of an inducer for inducing the apoptosis of the tumor cells. The preparation method of the chalcone derivative comprises: (1) synthesis of 2,6-dimethoxy quinone; (2) synthesis of 2,6-dimethoxy-p-hydroxybenzene; (3) synthesis of 2-hydroxy-4,6-dimethoxy-5-acetyl acetophenone complex; (4) synthesis of 3,6-dihydroxy-2,4-dimethoxy-acetophenone; (5) synthesis of 2-hydroxy-4,5,6-trimethoxy acetophenone; and (6) synthesis of 2',3-dihydroxy-4,4',5',6'-tetramethoxy chalcone. The preparation method provided by the invention is used for the preparation of 2',3-dihydroxy-4,4',5',6'-tetramethoxy chalcone and the inducer used for inducing the apoptosis of the tumor cells.

The invention relates to medicine application of 20(S)-ginsenoside Rg3, in particular to application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating a non-small cell lung cancer. In the invention, selecting a human non-small cell lung cancer cell strain (A549 lung adenocarcinoma, H460 large cell lung cancer and LTEP-78 lung squamous carcinoma) to be inoculated under the skin of a naked mouse, and observing the influence of the SPG-Rg3 on the non-small cell lung cancer; and carrying out CD34 immunohistochemistry staining and TUNEL immunofluorescence staining on tumor tissues, and observing the influence of the SPG-Rg3 on tumor angiogenesis and apoptosis. The inclusion proves that the 20(S)-ginsenoside Rg3 can remarkably inhibit the growth of the non-small cell lung cancer, has the action mechanism related with the promotion of the tumor apoptosis and the inhibition of the tumor angiogenesis and unobvious cooperation action when being combined with cyclophosphamide for application, and can be used for the clinical chemotherapy of the non-small cell lung cancer.